{
    "title": "103_hr695",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Women's Health Research Act of \n1993''.\n\nSEC. 2. ESTABLISHMENT OF OFFICE OF RESEARCH ON WOMEN'S HEALTH.\n\n    (a) In General.--Title IV of the Public Health Service Act, as \namended by section 2 of Public Law 101-613, is amended--\n            (1) by redesignating section 486 as section 485A;\n            (2) by redesignating parts F through H as parts G through \n        I, respectively; and\n            (3) by inserting after part E the following new part:\n\n                  ``Part F--Research on Women's Health\n\n``SEC. 486. OFFICE OF RESEARCH ON WOMEN'S HEALTH.\n\n    ``(a) Establishment.--There is established within the Office of the \nDirector of NIH an office to be known as the Office of Research on \nWomen's Health (in this part referred to as the `Office'). The Office \nshall be headed by a director, who shall be appointed by the Director \nof NIH.\n    ``(b) Purpose.--The Director of the Office shall--\n            ``(1) identify projects of research on women's health that \n        should be conducted or supported by the national research \n        institutes;\n            ``(2) identify multidisciplinary research relating to \n        research on women's health that should be so conducted or \n        supported;\n            ``(3) carry out paragraphs (1) and (2) with respect to the \n        aging process in women, with priority given to menopause;\n            ``(4) promote coordination and collaboration among entities \n        conducting research identified under any of paragraphs (1) \n        through (3);\n            ``(5) encourage the conduct of such research by entities \n        receiving funds from the national research institutes;\n            ``(6) recommend an agenda for conducting and supporting \n        such research;\n            ``(7) promote the sufficient allocation of the resources of \n        the national research institutes for conducting and supporting \n        such research;\n            ``(8) ensure that women are appropriately represented as \n        subjects in projects of clinical research conducted or \n        supported by the national research institutes; and\n            ``(9) prepare the report required in section 486B.\n    ``(c) Coordinating Committee.--\n            ``(1) In carrying out subsection (b), the Director of the \n        Office shall establish a committee to be known as the \n        Coordinating Committee on Research on Women's Health (hereafter \n        in this subsection referred to as the `Coordinating \n        Committee').\n            ``(2) The Coordinating Committee shall be composed of the \n        Directors of the national research institutes (or the designees \n        of the Directors).\n            ``(3) The Director of the Office shall serve as the chair \n        of the Coordinating Committee.\n            ``(4) With respect to research on women's health, the \n        Coordinating Committee shall assist the Director of the Office \n        in--\n                    ``(A) identifying the need for such research, and \n                making an estimate each fiscal year of the funds needed \n                to adequately support the research;\n                    ``(B) identifying needs regarding the coordination \n                of research activities, including intramural and \n                extramural multidisciplinary activities;\n                    ``(C) supporting the development of methodologies \n                to determine the circumstances in which obtaining data \n                specific to women (including data relating to the age \n                of women and the membership of women in ethnic or \n                racial groups) is an appropriate function of clinical \n                trials of treatments and therapies;\n                    ``(D) supporting the development and expansion of \n                clinical trials of treatments and therapies for which \n                obtaining such data has been determined to be an \n                appropriate function; and\n                    ``(E) encouraging the national research institutes \n                to conduct and support such research, including such \n                clinical trials.\n    ``(d) Advisory Committee.--\n            ``(1) In carrying out subsection (b), the Director of the \n        Office shall establish an advisory committee to be known as the \n        Advisory Committee on Research on Women's Health (hereafter in \n        this subsection referred to as the `Advisory Committee').\n            ``(2) The Advisory Committee shall be composed of no fewer \n        than 12, and not more than 18 individuals, who are not officers \n        or employees of the Federal Government. The Director of the \n        Office shall make appointments to the Advisory Committee from \n        among physicians, practitioners, scientists, and other health \n        professionals, whose clinical practice, research \n        specialization, or professional expertise includes a \n        significant focus on research on women's health. A majority of \n        the members of the Advisory Committee shall be women.\n            ``(3) The Director of the Office shall serve as the chair \n        of the Advisory Committee.\n            ``(4) The Advisory Committee shall--\n                    ``(A) advise the Director of the Office on \n                appropriate research activities to be undertaken by the \n                national research institutes with respect to--\n                            ``(i) research on women's health;\n                            ``(ii) research on gender differences in \n                        clinical drug trials, including responses to \n                        pharmacological drugs;\n                            ``(iii) research on gender differences in \n                        disease etiology, course, and treatment;\n                            ``(iv) research on obstetrical and \n                        gynecological health conditions, diseases, and \n                        treatments; and\n                            ``(v) research on women's health conditions \n                        which require a multidisciplinary approach;\n                    ``(B) report to the Director of the Office on such \n                research;\n                    ``(C) provide recommendations to such Director \n                regarding activities of the Office (including \n                recommendations on the development of the methodologies \n                described in subsection (c)(4)(C) and recommendations \n                on priorities in carrying out research described in \n                subparagraph (A)); and\n                    ``(D) assist in monitoring compliance with section \n                486(b)(8) regarding the inclusion of women in clinical \n                research.\n            ``(5)(A) The Advisory Committee shall prepare a biennial \n        report describing the activities of the Committee, including \n        findings made by the Committee regarding--\n                    ``(i) compliance with section 486(b)(8);\n                    ``(ii) the extent of expenditures made for research \n                on women's health by the agencies of the National \n                Institutes of Health; and\n                    ``(iii) the level of funding needed for such \n                research.\n            ``(B) The report required in subparagraph (A) shall be \n        submitted to the Director of NIH for inclusion in the report \n        required in section 403.\n    ``(e) Representation of Women Among Researchers.--The Secretary, \nacting through the Assistant Secretary for Personnel and in \ncollaboration with the Director of the Office, shall determine the \nextent to which women are represented among senior physicians and \nscientists of the national research institutes and among physicians and \nscientists conducting research with funds provided by such institutes, \nand as appropriate, carry out activities to increase the extent of such \nrepresentation.\n    ``(f) Definitions.--For purposes of this part:\n            ``(1) The term `women's health conditions', with respect to \n        women of all age, ethnic, and racial groups, means all \n        diseases, disorders, and conditions (including with respect to \n        mental health)--\n                    ``(A) unique to, more serious, or more prevalent in \n                women;\n                    ``(B) for which the factors of medical risk or \n                types of medical intervention are different for women, \n                or for which it is unknown whether such factors or \n                types are different for women; or\n                    ``(C) with respect to which there has been \n                insufficient clinical research involving women as \n                subjects or insufficient clinical data on women.\n            ``(2) The term `research on women's health' means research \n        on women's health conditions, including research on preventing \n        such conditions.\n\n``SEC. 486A. NATIONAL DATA SYSTEM AND CLEARINGHOUSE ON RESEARCH ON \n              WOMEN'S HEALTH.\n\n    ``(a) Data System.--\n            ``(1) The Director of NIH, in consultation with the \n        Director of the Office, shall establish a data system for the \n        collection, storage, analysis, retrieval, and dissemination of \n        information regarding research on women's health that is \n        conducted or supported by the national research institutes. \n        Information from the data system shall be available through \n        information systems available to health care professionals and \n        providers, researchers, and members of the public.\n            ``(2) The data system established under paragraph (1) shall \n        include a registry of clinical trials of experimental \n        treatments that have been developed for research on women's \n        health. Such registry shall include information on subject \n        eligibility criteria, sex, age, ethnicity or race, and the \n        location of the trial site or sites. Principal investigators of \n        such clinical trials shall provide this information to the \n        registry within 30 days after it is available. Once a trial has \n        been completed, the principal investigator shall provide the \n        registry with information pertaining to the results, including \n        potential toxicities or adverse effects associated with the \n        experimental treatment or treatments evaluated.\n    ``(b) Clearinghouse.--The Director of NIH, in consultation with the \nDirector of the Office and with the National Library of Medicine, shall \nestablish, maintain, and operate a program to provide information on \nresearch and prevention activities of the national research institutes \nthat relate to research on women's health.\n\n``SEC. 486B. BIENNIAL REPORT.\n\n    ``(a) In General.--With respect to research on women's health, the \nDirector of the Office shall, not later than February 1, 1994, and \nbiennially thereafter, prepare a report--\n            ``(1) describing and evaluating the progress made during \n        the preceding 2 fiscal years in research and treatment \n        conducted or supported by the National Institutes of Health;\n            ``(2) describing and analyzing the professional status of \n        women physicians and scientists of such Institutes, including \n        the identification of problems and barriers regarding \n        advancements;\n            ``(3) summarizing and analyzing expenditures made by the \n        agencies of such Institutes (and by such Office) during the \n        preceding 2 fiscal years; and\n            ``(4) making such recommendations for legislative and \n        administrative initiatives as the Director of the Office \n        determines to be appropriate.\n    ``(b) Inclusion in Biennial Report of Director of NIH.--The \nDirector of the Office shall submit each report prepared under \nsubsection (a) to the Director of NIH for inclusion in the report \nsubmitted to the President and the Congress under section 403.\n\n``SEC. 486C. AUTHORIZATION OF APPROPRIATIONS.\n\n    ``For the purpose of carrying out this part, there are authorized \nto be appropriated $25,000,000 for fiscal year 1994, and such sums as \nmay be necessary for each of the fiscal years 1995 and 1996.''.\n    (b) Requirement of Sufficient Allocation of Resources of \nInstitutes.--Section 402(b) of the Public Health Service Act (42 U.S.C. \n282(b)) is amended--\n            (1) in paragraph (10), by striking ``and'' after the \n        semicolon at the end;\n            (2) in paragraph (11), by striking the period at the end \n        and inserting ``; and''; and\n            (3) by inserting after paragraph (11) the following new \n        paragraph:\n            ``(12) after consultation with the Director of the Office \n        of Research on Women's Health, shall ensure that resources of \n        the National Institutes of Health are sufficiently allocated \n        for projects of research on women's health that are identified \n        under section 486(b).''.\n\nSEC. 3. OBSTETRICS AND GYNECOLOGY PROGRAM OF NATIONAL INSTITUTE OF \n              CHILD HEALTH AND HUMAN DEVELOPMENT.\n\n    Subpart 7 of part C of title IV of the Public Health Service Act \n(42 U.S.C. 285g et seq.) is amended by adding at the end the following \nsection:\n\n             ``program regarding obstetrics and gynecology\n\n    ``Sec. 452A. The Director of the Institute shall establish and \nmaintain within the Institute an intramural laboratory and clinical \nresearch program in obstetrics and gynecology.''."
}